Kelly Thomas P.'s most recent trade in Deciphera Pharmaceuticals Inc was a trade of 69,100 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 15, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Deciphera Pharmaceuticals Inc | Kelly Thomas P. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 69,100 | 69,100 | - | - | Stock Option (Right to Buy) | |
| Deciphera Pharmaceuticals Inc | Kelly P. Thomas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 17,275 | 83,360 (0%) | 0% | 0 | Common Stock | |
| Deciphera Pharmaceuticals Inc | Kelly Thomas P. | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 15.62 per share. | 15 Feb 2024 | 3,010 | 80,350 (0%) | 0% | 15.6 | 47,009 | Common Stock |
| Deciphera Pharmaceuticals Inc | Thomas P. Kelly | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.47 per share. | 16 Jan 2024 | 2,435 | 66,085 (0%) | 0% | 14.5 | 35,234 | Common Stock |
| Deciphera Pharmaceuticals Inc | P. Thomas Kelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2023 | 8,244 | 71,312 (0%) | 0% | - | Common Stock | |
| Deciphera Pharmaceuticals Inc | P. Kelly Thomas | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 15.37 per share. | 12 Dec 2023 | 2,792 | 68,520 (0%) | 0% | 15.4 | 42,905 | Common Stock |
| Deciphera Pharmaceuticals Inc | Thomas P. Kelly | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.40 per share. | 16 Jun 2023 | 1,655 | 57,140 (0%) | 0% | 14.4 | 23,835 | Common Stock |
| Deciphera Pharmaceuticals Inc | Thomas P. Kelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 65,900 | 65,900 | - | - | Stock Option (Right to Buy) | |
| Deciphera Pharmaceuticals Inc | Thomas P. Kelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 16,488 | 60,165 (0%) | 0% | 0 | Common Stock | |
| Deciphera Pharmaceuticals Inc | Thomas P. Kelly | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 15.10 per share. | 15 Feb 2023 | 1,370 | 58,795 (0%) | 0% | 15.1 | 20,686 | Common Stock |
| Deciphera Pharmaceuticals Inc | Thomas P. Kelly | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.24 per share. | 17 Jan 2023 | 2,403 | 43,677 (0%) | 0% | 21.2 | 51,043 | Common Stock |
| Deciphera Pharmaceuticals Inc | Thomas P. Kelly | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 10.75 per share. | 16 Jun 2022 | 1,768 | 46,080 (0%) | 0% | 10.8 | 19,006 | Common Stock |
| Deciphera Pharmaceuticals Inc | Thomas P. Kelly | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 9.05 per share. | 16 Feb 2022 | 1,368 | 47,848 (0%) | 0% | 9.0 | 12,380 | Common Stock |
| Deciphera Pharmaceuticals Inc | Thomas P. Kelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 82,000 | 82,000 | - | - | Stock Option (Right to Buy) | |
| Deciphera Pharmaceuticals Inc | Thomas P. Kelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 20,500 | 49,216 (0%) | 0% | 0 | Common Stock | |
| Deciphera Pharmaceuticals Inc | Thomas P. Kelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 49,900 | 49,900 | - | - | Stock Option (Right to Buy) | |
| Deciphera Pharmaceuticals Inc | Thomas P. Kelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 11,100 | 17,616 (0%) | 0% | 0 | Common Stock | |
| Deciphera Pharmaceuticals Inc | Thomas P. Kelly | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 48.87 per share. | 16 Feb 2021 | 524 | 6,516 (0%) | 0% | 48.9 | 25,608 | Common Stock |
| Deciphera Pharmaceuticals Inc | Thomas P. Kelly | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 50.01 per share. | 14 Sep 2020 | 3,000 | 7,040 (0%) | 0% | 50.0 | 150,036 | Common Stock |
| Deciphera Pharmaceuticals Inc | Thomas P. Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 14 Sep 2020 | 3,000 | 10,040 (0%) | 0% | 1.9 | 5,670 | Common Stock |
| Deciphera Pharmaceuticals Inc | Thomas P. Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2020 | 3,000 | 47,008 | - | - | Stock Option (Right to Buy) | |
| Deciphera Pharmaceuticals Inc | Thomas P. Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 08 Sep 2020 | 6,000 | 13,040 (0%) | 0% | 1.9 | 11,340 | Common Stock |
| Deciphera Pharmaceuticals Inc | Thomas P. Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Sep 2020 | 6,000 | 53,008 | - | - | Stock Option (Right to Buy) | |
| Deciphera Pharmaceuticals Inc | Thomas P. Kelly | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 45.23 per share. | 08 Sep 2020 | 3,700 | 8,540 (0%) | 0% | 45.2 | 167,349 | Common Stock |
| Deciphera Pharmaceuticals Inc | Thomas P. Kelly | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 47.71 per share. | 08 Sep 2020 | 3,000 | 7,040 (0%) | 0% | 47.7 | 143,126 | Common Stock |
| Deciphera Pharmaceuticals Inc | Thomas P. Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 08 Sep 2020 | 3,000 | 10,040 (0%) | 0% | 1.9 | 5,670 | Common Stock |
| Deciphera Pharmaceuticals Inc | Thomas P. Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Sep 2020 | 3,000 | 50,008 | - | - | Stock Option (Right to Buy) | |
| Deciphera Pharmaceuticals Inc | Thomas P. Kelly | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 46.55 per share. | 08 Sep 2020 | 1,500 | 7,040 (0%) | 0% | 46.6 | 69,825 | Common Stock |
| Deciphera Pharmaceuticals Inc | Thomas P. Kelly | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 44.70 per share. | 08 Sep 2020 | 800 | 12,240 (0%) | 0% | 44.7 | 35,756 | Common Stock |